MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with V

Vigabatrin

Vigabatrin 100mg soluble tablets sugar free

No stability information

Stability notes for Vigabatrin 100mg soluble tablets sugar free

There are no stability notes for this medicine.

Supplier

Kigabeq 100mg soluble tablets (Orphalan UK Ltd)

Vigabatrin 500mg soluble tablets sugar free

No stability information

Stability notes for Vigabatrin 500mg soluble tablets sugar free

There are no stability notes for this medicine.

Supplier

Kigabeq 500mg soluble tablets (Orphalan UK Ltd)

Vigabatrin 500mg tablets

Compatible

Stability notes for Vigabatrin 500mg tablets

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Sabril 500mg tablets (Sanofi).

Supplier

Sabril 500mg tablets (Sanofi)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.